Meningococcal vaccines

Expert Review of Vaccines

Volumn 1, Issue 1, 2002, Pages 75-84

  Bethell, Delia ^a   Pollard, Andrew J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Capsular switching; Conjugate vaccines; Lipopolysaccharide; Meningococcal vaccines; Neisseria meningitidis; Outer membrane proteins; Whole genome sequencing

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; GLYCOCONJUGATE; IMMUNOGLOBULIN G ANTIBODY; LIVE VACCINE; MENINGOCOCCUS VACCINE; OUTER MEMBRANE PROTEIN; POLYSACCHARIDE;

BACTEREMIA; BACTERIAL GENOME; BLOOD CULTURE; CEREBROSPINAL FLUID CULTURE; CLINICAL FEATURE; CLINICAL TRIAL; CONJUGATE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEVER; FLUID THERAPY; HUMAN; IMMUNIZATION; LATEX AGGLUTINATION TEST; MENINGOCOCCOSIS; MORTALITY; NEISSERIA MENINGITIDIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RASH; REVIEW; SEPTICEMIA; SERUM BACTERICIDAL ACTIVITY; UNITED KINGDOM; VACCINATION;

ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL VACCINES; GENOME, BACTERIAL; HUMANS; MENINGITIS, MENINGOCOCCAL; NEISSERIA MENINGITIDIS; POLYSACCHARIDES; VACCINES, CONJUGATE;

EID: 0037938812     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.1.1.75     Document Type: Review

References (97)

1. Tikhomirov EM. Santamaria and K. Esteves, Meningococcal disease: public health burden and control World Health Stat. Q. 50(3-4), 170-177 (1997).
2. Gold R et al. Carriage of Neisseria meningitidis and Neisseria lactamica in infants and children. J. Infect. Dis. 137(2), 112-121 (1978).
3. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. II. Development of natural immunity. J. Exp. Med 129(6), 1327-1348 (1969).
4. Sim RJ et al. Underestimation of meningococci in tonsillar tissue by nasopharyngeal swabbing. Lancet 356(9242), 1653-1654 (2000).
5. Mitchell MS, DL Rhoden, EO King. Lacrose fermenting organisms resembling Neisseria meningitidis. J Bacteriol. 90, 560 (1965).
6. Riordan T et al. Acquisition and carriage of meningococci in marine commando recruits. Epidemiol. Infect. 121(3), 495-505 (1998).
7. Neal KR et al. Changing carriage rate of Neisseria meningitidis among university students during the first week of term: cross sectional study Br. Med J. 320(7238), 846-849 (2000).
8. Rake G. Studies on meningococcus infection VI. The carrier problem. J. Exp. Med. 59, 553-576 (1934).
9. Ala'Aldeen DA et al. Dynamics of meningococcal long-term carriage among university students and their implications for mass vaccination. J. Clin. Microbiol. 38(6), 2311-2316 (2000).
10. Blakebrough IS et al. The epidemiology of infections due to Neisseria meningitidis and Neisseria lactamica in a northern Nigerian community. J. Infect. Dis. 146(5), 626-637 (1982).
11. De Wals P et al. Longitudinal study of asymptomatic meningococcal carriage in two Belgian populations of schoolchildren. J. Infect. 6(2), 147-156 (1983).
12. Connolly M, Noah N. Is group C meningococcal disease increasing in Europe? A report of surveillance of meningococcal infection in Europe 1993-6. European Meningitis Surveillance Group. Epidemiol. Infect. 122(1), 41-49 (1999).
13. Rosenstein NE et al. The changing epidemiology of meningococcal disease in the United States, 1992-1996. J. Infect. Dis. 180(6), 1894-1901 (1999).
14. Pollard AJ, National Committee on Immunization (NACI). Statement on recommended use of meningococcal vaccines. Can. Comm Dis. Rev. 27(ACS6), 2-36 (2001).
15. Lapeyssonnie L. La meningite cerebrospinale en Afrique. Bull WHO 28 (Suppl. 1), 3-114 (1963).
16. Gray SJ et al. Ultrasound-enhanced latex immunoagglutination and PCR as complementary methods for nonculturebased confirmation of meningococcal disease. J Clin Microbiol. 37(6), 1797-1801 (1999).
17. Borrow R et al. Nonculture diagnosis and serogroup determination of meningococcal B and C infection by a sialyltransferase (siaD) PCR ELISA. Epidemiol. Infect. 118(2), 111-117 (1997).
18. Kaczmarski EB et al. Creating a national service for the diagnosis of meningococcal disease by polymerase chain reaction. Commun. Dis. Public Health 1(1), 54-56 (1998).
19. Booy R et al. Reduction in case fatality rate from meningococcal disease associated with improved healthcare delivery. Arch. Dis. Child. 85(5), 386-390 (2001).
20. Nadel S et al. Avoidable deficiencies in the delivery of healthcare to children with meningococcal disease. J. Accid Emerg. Med. 15, 298-303 (1998).
21. Pollard AJ et al. Emergency management of meningococcal disease. Arch. Dis. Child. 80(3), 290-296 (1999).
22. Gheesling LL et al. Multicenter comparison of Neisseria meningitidis serogroup C anti capsular polysaccharide antibody levels measured by a standardized enzyme-linked immunosorbent assay. J. Clin. Microbiol. 32(6), 1475-1482 (1994).
23. Peltola H. Meningococcal vaccines. Current status and future possibilities. Drugs 55(3), 347-366 (1998).
24. Granoff DM et al. A modified enzyme-linked immunosorbent assay for measurement of antibody responses to meningococcal C polysaccharide that correlate with bactericidal responses. Clin. Diagn. Lab. Immunol. 5(4), 479-485 (1998).
25. Maslanka SE et al. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group. Clin. Diagn. Lab. Immunol. 4(2), 156-167 (1997).
26. World Health Organisation, Requirements for meningococcal polysaccharide vaccine. World Health Organisation technical report series. Vol. 594. Geneva: World Health Organisation (1956).
27. Borrow R et al. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: re-evaluation of correlates of protection. Infect. Immun. 69(3), 1568-1573 (2001).
28. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J. Exp. Med. 129(6), 1307-1326 (1969).
29. Zollinger WD, Mandrell RE. Importance of complement source in bactericidal activity of human antibody and murine monoclonal antibody to meningococcal group B polysaccharide. Infect. Immun. 40(1), 257-264 (1983).
30. Milagres LG et al. Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy. Infect. Immun. 62(10), 4419-4424 (1994).
31. Lehmann AK, Halstensen A, Bassoe CF. Flow cytometric quantitation of human opson-independent phagocytosis and oxidative burst responses to meningococcal antigens Cytometry 33(4), 406-413 (1998).
32. Lehmann AK et al. Human opsonins induced during meningococcal disease recognize transferrin binding protein complexes. Infect. Immun. 67(12), 6526-6532 (1999).
33. Ross SC et al. Killing of Neisseria meningitidis by human neutrophils: implications for normal and complement-deficient individuals. J. Infect. Dis. 155(6), 1266-1275 (1987).
34. Ison CA et al. Assessment of immune response to meningococcal disease: comparison of a whole-blood assay and the serum bactericidal assay. Microb. Pathog. 27(4), 207-214 (1999).
35. Finne J et al. An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues. J. Immunol. 138(12), 4402-4407 (1987).
36. Swartley JS et al. Capsule switching of Neisseria meningitidis. Proc. Natl Acad. Sci. USA 94(1), 271-276 (1997).
37. Maiden MC, Spratt BG. Meningococcal conjugate vaccines: new opportunities and new challenges. Lancet 354(9179), 615-616 (1999).
38. De Wals P, De Serres G, Niyonsenga T. Effectiveness of a mass immunization campaign against serogroup C meningococcal disease in Quebec. JAMA 285(2), 177-181 (2001).
39. De Wals P et al. Impact of a mass immunization campaign against serogroup C meningococcus in the Province of Quebec, Canada. Bull. World. Health. Organ. 74(4), 407-411 (1996).
40. Salleras L, Dominguez A, Prats G. Control of serogroup C meningococcal meningitis by mass vaccination in Catalonia (Spain). Vaccine 17(Suppl. 3), S56-60 (1999).
41. Biselli R et al. Dramatic reduction of meningococcal meningitis among military recruits in Italy after introduction of specific vaccination. Vaccine 11 (5), 578-581 (1993).
42. Rosenstein N et al. Efficacy of meningococcal vaccine and barriers to vaccination. JAMA 279(6), 435-439 (1998).
43. Artenstein MS, Brandt BL. Immunologic hyporesponsiveness in man to group C meningococcal polysaccharide. J. Immunol. 115(1), 5-7 (1975).
44. MacLennan J et al. Immune response to revaccination with meningococcal A and C polysaccharides in Gambian children following repeated immunisation during early childhood. Vaccine 17(23-24), 3086-3093 (1999).
45. Peltola H et al. Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age. N. Engl. J. Med 297(13), 686-691 (1977).
46. Law BJ et al. Age-related immunogenicity of meningococcal polysaccharide vaccine in aboriginal children and adolescents living in a Northern Manitoba reserve community. Pediatr. Infect. Dis. J. 17(10), 860-864 (1998).
47. Booy R et al. Efficacy of Haemophilus influenzae type b conjugate vaccine PRP-T Lancet 344(8919), 362-366 (1994).
48. MacLennan J et al. Immunologic memory 5 years after meningococcal A/C conjugate vaccination in infancy J. Infect. Dis. 183(1), 97-104 (2001).
49. MacLennan JM et al. Safety, immunogenicity and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: A randomized controlled trial [see comments]. JAMA 283(21), 2795-801 (2000).
50. Cartwright K, Noah N, Peltola H. Meningococcal disease in Europe: epidemiology, mortality and prevention with conjugate vaccines. Vaccine 19, 4347-4356 (2001).
51. Miller E, Salisbury D, Ramsay M. Planning, registration and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 20(Suppl.1), S58-67 (2001).
52. Ramsay ME et al. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet 357(9251), 195-196 (2001).
53. Morley SL, AJ Pollard. Vaccine prevention of meningococcal disease, coming soon? Vaccine 20(5-6), 666-687 (2001).
54. Fusco PC et al. Preclinical evaluation of a novel group B meningococcal conjugate vaccine that elicits bactericidal activity in both mice and nonhuman primates. J. Infect Dis. 175(2), 364-372 (1997).
55. Frasch CE. Meningococcal Vaccines: past present and future, in Meningococcal disease. Cartwright K, Ed. John Wiley and Sons, New York, NY, USA. 245-283 (1995).
56. Zollinger WD et al. Safety and immunogenicity of a Neisseria meningitidis Type 2 protein vaccine in animals and humans. J. Infect Dis. 137(6), 728-739 (1978).
57. Frasch CE et al. Outer membrane protein vesicle vaccines for meningococcal disease, in Meningococcal Vaccines. Pollard AJ, Maiden MC (Eds.). Humana Press: Totowa, NJ, USA 81-107 (2001).
58. Sierra GV et al. Vaccine against group B Neisseria meningitidis, protection trial and mass vaccination results in Cuba. NIPH Ann. 14(2), 195-207, discussion 208-210 (1991).
59. de Moraes JC et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet 340(8827), 1074-1078 (1992).
60. Noronha CP, Struchiner CJ, Halloran ME. Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case-control study Int. J. Epidemiol. 24(5), 1050-1057 (1995).
61. Bjune G et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 338(8775), 1093-1096 (1991).
62. Tappero JW et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA 281(16), 1520-1527 (1999).
63. Perkins BA et al. Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. J. Infect. Dis. 177(3), 683-691 (1998).
64. Van Der Ley P, Poolman JT. Construction of a multivalent meningococcal vaccine strain based on the class 1 outer membrane protein. Infect. Immun. 60(8), 3156-3161 (1992).
65. Claassen I et al. Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine. Vaccine 14(10), 1001-1008 (1996).
66. Cartwright K et al. Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins. Vaccine 17(20-21), 2612-2619 (1999).
67. de Kleijn ED et al. Immunogenicity and safety of a hexavalent meningococcal outermembrane-vesicle vaccine in children of 2-3 and 7-8 years of age. Vaccine 18(15), 1456-1466 (2000).
68. Martin D et al. Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection. J Exp. Med 185(7), 1173-1183 (1997).
69. Moe GR, Tan S, Granoff DM. Differences in surface expression of NspA among Neisseria meningitidis group B strains. Infect. Immun. 67(11), 5664-5675 (1999).
70. Lissolo L et al. Evaluation of transferrinbinding protein 2 within the transferrinbinding protein complex as a potential antigen for future meningococcal vaccines. Infect. Immun. 63(3), 884-890 (1995).
71. Abdel-Hadi H et al. Investigation of the potential of App as a vaccine candidatein Twelth International Neisseria conference. Galveston, HCC Inc. TX, USA (2000).
72. Gomez JA, MT Criado, CM Ferreiros. Bactericidal activity of antibodies elicited against the Neisseria meningitidis 37-kDa ferric binding protein (FbpA) with different adjuvants. FEMS Immunol Med. Microbiol. 20(1), 79-86 (1998).
73. Carson SD et al. Ferric enterobactin binding and utilization by Neisseria gonorrhoeae. J. Bacteriol. 181(9), 2895-2901 (1999).
74. Ala'Aldeen DA, HA Davies, SP Borriello. Vaccine potential of meningococcal FrpB: studies on surface exposure and functional attributes of common epitopes. Vaccine 12(6), 535-541 (1994).
75. Johnson AS et al. Analysis of the human Ig isotype response to lactoferrin binding protein A from Neisseria meningitidis. FEMS Immunol. Med Microbiol. 25(4), 349-354 (1995).
76. Virji M et al. Meningococcal Opa and Opc proteins: their role in colonization and invasion of human epithelial and endothelial cells. Mol. Microbiol. 10(3), 499-510 (1993).
77. Stephens DS, McGee ZA. Attachment of Neisseria meningitidis to human mucosal surfaces: influence of pili and type of receptor cell. J. Infect. Dis. 143(4), 525-532 (1981).
78. Rosenqvist E et al. An ELISA study of the antibody response after vaccination with a combined meningococcal group B polysaccharide and serotype 2 outer membrane protein vaccine. NIPH Ann. 6(2), 139-149 (1983).
79. Munkley A et al. Blocking of bactericidal killing of Neisseria meningitidis by antibodies directed against class 4 outer membrane protein. Microb. Pathog. 11(6), 447-452 (1991).
80. Manning DS, Reschke DK, Judd RC. Omp85 proteins of Neisseria gonorrhoeae and Neisseria meningitidis are similar to Haemophilus influenzae D-15-Ag and Pasteurella multocida Oma87. Microb. Pathog. 25(1), 11-21 (1998).
81. Peak IR et al. Identification and characterisation of a novel conserved outer membrane protein from Neisseria meningitidis. FEMS Immunol. Med Microbiol. 28(4), 329-334 (2000).
82. Collins RF et al. Analysis of the PilQ secretin from Neisseria meningitidis by transmission electron microscopy reveals a dodecameric quaternary structure. J. Bacteriol. 183(13), 3825-3832 (2001).
83. Davies RL, Wall RA, Borriello SP. Comparison of methods for the analysis of outer membrane antigens of Neisseria meningitidis by western blotting. J. Immunol Meth. 134(2), 215-225 (1990).
84. Lewis LA et al. Molecular characterization of hpuAB, the haemoglobin-haptoglobin-utilization operon of Neisseria meningitidis. Mol. Microbiol. 23(4), 737-749 (1997).
85. Tettelin H et al. Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science 287(5459), 1809-1815 (2000).
86. Parkhill J et al. Complete DNA sequence of a serogroup A strain of Neisseria meningitidis Z2491. Nature 404(6777), 502-506 (2000).
87. Poolman J, Berthet FX. Alternative vaccine strategies to prevent serogroup B meningococcal diseases. Vaccine 20(Suppl. 1), S24-26 (2001).
88. Pizza M et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 287(5459), 1816-1820 (2000).
89. Giuliani MM et al. Immunogenicity and bactericidal activity of conserved N. meningitidis serogroup B antigens. in Twelfth International Pathogenic Neisseria Conference. Galveston: Healthcare Communications, Inc TX, USA (2001).
90. Brett PJ, Feavers I, Charalambous BM. Identification of peptides that mimic N. meningitidis LOS epitopes via the use of combinatorial phage-display libraries, in Meningococcal Vaccines, Pollard AJ, Maiden MC, Editors. Humana Press: Totowa, NJ, USA 181-197 (2001).
91. Grothaus MC et al. Selection of an immunogenic peptide mimic of the capsular polysaccharide of Neisseria meningitidis serogroup A using a peptide display library Vaccine 18(13), 1253-1263 (2000).
92. Saukkonen K et al. Comparative evaluation of potential components for group B meningococcal vaccine bypassive protection in the infant rat and in vitro bactericidal assay. Vaccine 7(4), 325-328 (1989).
93. Andersen SR et al. Short-chain lipopolysaccharide mutants of serogroup B Neisseria meningitidis of potential value for production of outer membrane vesicle vaccines. Microb. Pathog 19(3), 159-168 (1995).
94. Andersen SR. et al. Outer membrane vesicle vaccines made from short-chain lipopolysaccharide mutants of serogroup B Neisseria meningitidis: effect of the carbohydrate chain length on the immune response Vaccine 15(11) 1225-1234 (1999).
95. Plested JS et al. Conservation and accessibility of an inner core lipopolysaccharide epitope of Neisseria meningitidis. Infect. Immun. 67(10) 5417-5426 (1999).
96. Tang C, Moxon R, Levine MM. For discussion: live attenuated vaccines for group B meningococcus. Vaccine 17(2) 114-117 (1999).
97. Oftung F et al. Antigen-specific T-cell responses in humans after intranasal immunization with a meningococcal serogroup B outer membrane vesicle vaccine. Infect. Immun. 67(2), 921-927 (1999).